1Qiu c, Luthy DA, Zhang C, et al. A prospective study of maternal serum C-reactive protein concentrations and risk of preeclampsia. Am J Hypertens,2004,17:154-160.
2ACOG Committee on Obstetric Practice. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet,2002,77:67-75.
3Topalak O, Saygili U, Soyturk M, et al. Serum, pleural dffusion, and ascites CA-125 levels in ovarian cancer and nonovarian benigh and malignant diseases: a comparative study. Gynecol Oncol,2002,85 : 108-113.
4Zeirnet AG, Marth C, Offner FA ,et al. Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA- 125. Gynecol Oncol, 1996,62:384-389.
5Homstein M, Thomas PP, Gleason RE, et al. Menstrual cyclicity of CA 125 in patients with endometriosis. Fertil Steril, 1992,58:279-283.
6Jager W, Diedrich K, Wildt L. Elevated levels of CA-125 in serum of patients suffering from ovarian hyperstimulation syndrome. Fertil Steril, 1987,48:675-678.
7Halila H,Stenman UH, Seppala M. Ovarian cancer antigen CA 125 leves in pelvic inflammatory disease and pregnancy. Cancer, 1986,57: 1327- 1329.
8Bon GG,Kenemans P, Verstraeten AA, et al. Maternal serum Ca125 and Ca15-3 antigen levels in normal and pathological pregnancy. Fetal Diagn Ther,2001,16 : 166,172.
9Schrcksnadel H, Daxenbichler G, Artner E, et al. Tumor markers in hypertensive disorders of pregnancy. Gynecol Obstet Invest, 1993,35 : 204 -208.
10Lelle RJ, Henkel E, Leinemann D, et al. Measurement of CEA, TPA, neopterin,CA125, GA153 and CA199 in sera of pregnant women, umbilical cord blood and amniotic fluid. Gynecol Obstet Invest, 1989, 27 : 137-142.
